Acknowledgments We thank Dr Keith Leung and Prof. Kathy Cheah for helping with the embryo re-derivation experiment. Adiponectin knockout mice were kindly provided by Dr. Lawrence Chan at Baylor College of Medicine. References 1. Pischon T, Nothlings U, Boeing H (2008) Obesity and cancer. Proc Nutr Soc 67: 128–145. 2. McTiernan A (2005) Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 19: 871–881; discussion 881– 872, 885–876. 3. Bray GA (2004) Medical consequences of obesity. J Clin Endocrinol Metab 89: 2583–2589. 4. Housa D, Housova J, Vernerova Z, Haluzik M (2006) Adipocytokines and cancer. Physiol Res 55: 233–244. 5. Baillargeon J, Rose DP (2006) Obesity, adipokines, and prostate cancer (review). Int J Oncol 28: 737–745. 6. Berstein LM (2005) [Hormones of adipose tissue (adipocytokines): ontogenetic and oncologic aspects]. Adv Gerontol 16: 51–64. 7. Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5: 153–165. 8. Wang Y, Lam KS, Yau MH, Xu A (2008) Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409: 623–633. 9. Trujillo ME, Scherer PE (2005) Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257: 167–175. 10. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86: s858–866. 11. Schaffler A, Scholmerich J, Buechler C (2007) Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3: 345–354. 12. Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14: 189–206. 13. Wang Y, Lam KS, Xu A (2007) Adiponectin as a negative regulator in obesity- related mammary carcinogenesis. Cell Res 17: 280–282. 14. Mistry T, Digby JE, Desai KM, Randeva HS (2007) Obesity and prostate cancer: a role for adipokines. Eur Urol 52: 46–53. 15. Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94: 1221–1225. 16. Koerner A, Kratzsch J, Kiess W (2005) Adipocytokines: leptin–the classical, resistin–the controversical, adiponectin–the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19: 525–546. 17. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, et al. (2008) Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 68: 3178–3184. 18. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, et al. (2007) Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92: 1041–1048. 19. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, et al. (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89: 1102–1107. 20. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, et al. (2007) Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 14: 669–677. 21. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, et al. (2007) Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 92: 1510–1516. 22. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al. (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699–5704. 23. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, et al. (2006) Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237: 109–114. 24. Kang JH, Yu BY, Youn DS (2007) Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 22: 117–121. 25. Pfeiler GH, Buechler C, Neumeier M, Schaffler A, Schmitz G, et al. (2008) Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19: 787–793. 26. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP (2008) Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98: 370–379. 27. Arditi JD, Venihaki M, Karalis KP, Chrousos GP (2007) Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39: 9–13. 28. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, et al. (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66: 11462–11470. Adiponectin and Breast Cancer Author Contributions Conceived and designed the experiments: AX YW. Performed the experiments: JBL KHC JL YW. Analyzed the data: JBL KHC AX YW. Contributed reagents/materials/analysis tools: AX KL NSW RTM PS GC YW. Wrote the paper: JBL KHC YW. 29. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, et al. (2006) Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345: 271–279. 30. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, et al. (2005) Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28: 1263–1269. 31. Nakayama S, Miyoshi Y, Ishihara H, Noguchi S (2007) Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat. 32. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, et al. (2008) T- cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 68: 1407–1416. 33. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Buechler C, et al. (2008) Antagonistic proliferative activities of adiponectin and leptin in breast cancer: study on MCF7 cells. Proc Nutr Soc 67: E184. 34. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, et al. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404: 449–458. 35. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, et al. (2005) Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4: 271–279. 36. Tamura T, Stadtman TC (2002) Mammalian thioredoxin reductases. Methods Enzymol 347: 297–306. 37. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954–961. 38. Ma K, Cabrero A, Saha PK, Kojima H, Li L, et al. (2002) Increased beta - oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277: 34658–34661. 39. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, et al. (2007) Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 13: 2168–2177. 40. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A 96: 10182–10187. 41. Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104: 12288–12293. 42. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874. 43. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, et al. (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38: 197–204. 44. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF (2008) The PTEN/ PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187–198. 45. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G (2004) Thioredoxin- 1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN’s tumor suppressor activity. Arch Biochem Biophys 429: 123–133. 46. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26: 1338–1345. 47. Tamguney T, Stokoe D (2007) New insights into PTEN. J Cell Sci 120: 4071–4079. 48. Leslie NR, Downes CP (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382: 1–11. 49. Arne´r ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102–6109. 50. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, et al. (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105: 3921–3926. 51. Zhao H, Cui Y, Dupont J, Sun H, Hennighausen L, et al. (2005) Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res 65: 6864–6873. 52. Kim SE, Lee WJ, Choi KY (2007) The PI3 kinase-Akt pathway mediates Wnt3a-induced proliferation. Cell Signal 19: 511–518. 53. Tureckova´ J, Kucerova´ D, Vojtechova´ M, Sloncova´ E, Tuha´ckova´ Z (2006) Expression of beta-catenin is regulated by PI-3 kinase and sodium butyrate in colorectal cancer cells. Int J Mol Med 17: 69–75. 54. Naito AT, Akazawa H, Takano H, Minamino T, Nagai T, et al. (2005) Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling. Circ Res 97: 144–151. PLoS ONE | www.plosone.org 15 March 2009 | Volume 4 | Issue 3 | e4968